Arcutis Biotherapeutics Inc Cash Flow-to-Debt Ratio
Arcutis Biotherapeutics Inc cash flow-to-debt ratio. Arcutis Biotherapeutics Inc (ARQT) has a Cash Flow-to-Debt Ratio of 0.05x as of June 2026, meaning its operating cash flow of $12.64 Million could theoretically repay 0% of its total liabilities ($267.96 Million) in one year. Check cash flow quality index of Arcutis Biotherapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Arcutis Biotherapeutics Inc (2017–2025)
Cash flow-to-debt ratio of Arcutis Biotherapeutics Inc from 2017 to 2025. Historical debt coverage capacity for Arcutis Biotherapeutics Inc across 9 annual periods. Check ARQT total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Arcutis Biotherapeutics Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
Arcutis Biotherapeutics Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Arcutis Biotherapeutics Inc. For the full cash flow conversion analysis, see Arcutis Biotherapeutics Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | $-5.62 Million | $243.49 Million | ▲ +96.1% |
| 2024 | -0.59x | $-112.16 Million | $191.35 Million | ▲ +40.0% |
| 2023 | -0.98x | $-247.06 Million | $252.70 Million | ▲ +9.1% |
| 2022 | -1.08x | $-257.71 Million | $239.69 Million | ▲ +32.0% |
| 2021 | -1.58x | $-174.63 Million | $110.47 Million | ▲ +61.3% |
| 2020 | -4.09x | $-113.03 Million | $27.65 Million | ▲ +47.0% |
| 2019 | -7.72x | $-42.84 Million | $5.55 Million | ▼ -4014.5% |
| 2018 | -0.19x | $-14.09 Million | $75.08 Million | ▲ +56.2% |
| 2017 | -0.43x | $-3.77 Million | $8.81 Million | — |